- Home
- BTBD vs CELZ Comparison
BTBD vs CELZ Comparison
Compare BTBD & CELZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- CELZ
- Stock Information
- Founded
- BTBD 1987
- CELZ 1998
- Country
- BTBD United States
- CELZ United States
- Employees
- BTBD N/A
- CELZ N/A
- Industry
- BTBD Restaurants
- CELZ Biotechnology: Pharmaceutical Preparations
- Sector
- BTBD Consumer Discretionary
- CELZ Health Care
- Exchange
- BTBD Nasdaq
- CELZ Nasdaq
- Market Cap
- BTBD 8.3M
- CELZ 6.8M
- IPO Year
- BTBD 2021
- CELZ N/A
- Fundamental
- Price
- BTBD $1.27
- CELZ $2.79
- Analyst Decision
- BTBD
- CELZ
- Analyst Count
- BTBD 0
- CELZ 0
- Target Price
- BTBD N/A
- CELZ N/A
- AVG Volume (30 Days)
- BTBD 3.1K
- CELZ 64.5K
- Earning Date
- BTBD 08-12-2025
- CELZ 08-08-2025
- Dividend Yield
- BTBD N/A
- CELZ N/A
- EPS Growth
- BTBD N/A
- CELZ N/A
- EPS
- BTBD N/A
- CELZ N/A
- Revenue
- BTBD $14,864,398.00
- CELZ $14,000.00
- Revenue This Year
- BTBD N/A
- CELZ N/A
- Revenue Next Year
- BTBD N/A
- CELZ N/A
- P/E Ratio
- BTBD N/A
- CELZ N/A
- Revenue Growth
- BTBD 4.71
- CELZ 55.56
- 52 Week Low
- BTBD $1.00
- CELZ $1.69
- 52 Week High
- BTBD $2.02
- CELZ $6.90
- Technical
- Relative Strength Index (RSI)
- BTBD 43.34
- CELZ 67.22
- Support Level
- BTBD $1.32
- CELZ $2.62
- Resistance Level
- BTBD $1.36
- CELZ $2.80
- Average True Range (ATR)
- BTBD 0.03
- CELZ 0.20
- MACD
- BTBD -0.01
- CELZ 0.01
- Stochastic Oscillator
- BTBD 0.00
- CELZ 80.78
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.